Bicara Therapeutics Information Ratio
| BCAX Stock | | | 22.58 -0.51 -2.21% |
The Information Ratio measures excess return (alpha) per unit of tracking error relative to a benchmark. Unlike the Sharpe Ratio, which uses total volatility, the Information Ratio isolates only the variability of the alpha component — the return attributable to active decisions rather than passive market exposure. Below is Bicara Therapeutics's current Information Ratio with peer comparisons and related risk metrics.
Current Information Ratio Value
Bicara Therapeutics carries a Information Ratio of 0.1697, consistent with positive but modest excess return per unit of tracking risk. Bicara Therapeutics has outperformed its benchmark, though the margin is limited relative to the tracking error incurred.
INFOR | = | ER[a] - ER[b]STD[a] |
| = | 0.1697 | |
Information Ratio Peers Comparison
Bicara Therapeutics's Information Ratio of 0.1697 falls above the 0.05 peer average. Values range from -0.013 (Phathom Pharmaceuticals) to 0.1816 (Tango Therapeutics), with wide dispersion across the group. Bicara Therapeutics's risk-adjusted return exceeds the peer average, indicating more efficient compensation for risk taken.
Information Ratio Relative To Other Indicators
The chart below plots Information Ratio against Maximum Drawdown for Bicara Therapeutics and its peers. Each point represents one equity — position along the horizontal axis shows Information Ratio while the vertical axis shows Maximum Drawdown. Equities that cluster in different quadrants carry distinct risk-return profiles. Use the dropdowns to swap in other indicators for either axis.
Bicara Therapeutics's Maximum Drawdown of
12.53 runs about
73.84 times its Information Ratio of
0.17 . This indicates Maximum Drawdown substantially exceeds Information Ratio for Bicara Therapeutics.
Methodology, Assumptions & Data Sources
The current Information Ratio for Bicara Therapeutics is 0.1697. The Information Ratio for Bicara Therapeutics applies a standardized calculation to daily closing prices and, where applicable, volume data across the selected period. All inputs are based on exchange-reported closing prices, with adjustments for stock splits, dividends, and other corporate actions. Bicara Therapeutics operates in the health care sector, which may exhibit distinct volatility and momentum characteristics relative to the broader market. The output reflects the selected calculation window — changing the horizon will produce different readings. This stock metric is provided for analytical reference.
Other Technical Indicators